Vedolizumab Eases Severe IBD in Two Trials (CME/CE)

(MedPage Today) -- The monoclonal antibody vedolizumab was effective in many patients with active, refractory inflammatory bowel disease, although benefits were more pronounced for the subgroup of those with ulcerative colitis, two randomized trials found.
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news